These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 17416868)

  • 1. Single-agent chemotherapy for the treatment of elderly patients with advanced non-small-cell lung cancer: what is the best drug?
    Gridelli C; Maione P; Rossi A
    J Clin Oncol; 2007 Apr; 25(11):1444-5; author reply 1446. PubMed ID: 17416868
    [No Abstract]   [Full Text] [Related]  

  • 2. Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer: results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904).
    Kudoh S; Takeda K; Nakagawa K; Takada M; Katakami N; Matsui K; Shinkai T; Sawa T; Goto I; Semba H; Seto T; Ando M; Satoh T; Yoshimura N; Negoro S; Fukuoka M
    J Clin Oncol; 2006 Aug; 24(22):3657-63. PubMed ID: 16877734
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Docetaxel combination produces 2-year survival advantage in NSCLC patients.
    Oncology (Williston Park); 2001 Dec; 15(12):1559, 1564. PubMed ID: 11780700
    [No Abstract]   [Full Text] [Related]  

  • 4. Combination regimens and dose intensification in non-small cell lung cancer: a panel discussion (Part 1).
    Crawford J; Chang AY; Gralla RJ; Souquet PJ; Vokes EE
    Semin Oncol; 1996 Apr; 23(2 Suppl 5):22-4. PubMed ID: 8610233
    [No Abstract]   [Full Text] [Related]  

  • 5. Missing patient-reported outcome data in an adjuvant lung cancer study.
    Land SR
    J Clin Oncol; 2008 Nov; 26(31):5018-9. PubMed ID: 18809601
    [No Abstract]   [Full Text] [Related]  

  • 6. Elderly subgroup analysis of a randomized phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for first-line treatment of advanced nonsmall cell lung carcinoma (TAX 326).
    Belani CP; Fossella F
    Cancer; 2005 Dec; 104(12):2766-74. PubMed ID: 16288485
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Taxanes as first-line therapy for advanced non-small cell lung cancer: a systematic review and practice guideline.
    Chu Q; Vincent M; Logan D; Mackay JA; Evans WK;
    Lung Cancer; 2005 Dec; 50(3):355-74. PubMed ID: 16139391
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Docetaxel in combination with platinums in patients with advanced non-small-cell lung cancer.
    Belani CP
    Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):42-5. PubMed ID: 9364542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biweekly administration of docetaxel and vinorelbine as second-line chemotherapy for patients with stage IIIB and IV non-small cell lung cancer: a phase II study of the Galician Lung Cancer Group (GGCP 013-02).
    Vázquez S; Huidobro G; Amenedo M; Fírvida JL; León L; Lázaro M; Grande C; Mel JR; Ramos M; Salgado M; Casal J
    Anticancer Drugs; 2007 Nov; 18(10):1201-6. PubMed ID: 17893521
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Oral vinorelbine: pharmacology and treatment outcome in non-small cell bronchial carcinoma and breast carcinoma].
    Bartsch V
    Onkologie; 2006 Mar; 29 Suppl 1():1-28. PubMed ID: 16534241
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination docetaxel/vinorelbine for metastatic breast cancer and non-small-cell lung cancer.
    Aapro MS
    Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):46-9. PubMed ID: 9364543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concurrent chemoradiotherapy with vinorelbine and a platinum compound followed by consolidation chemotherapy for unresectable stage III non-small cell lung cancer: preliminary results of a phase II study.
    Rusu P; Ciuleanu TE; Cernea D; Pelau D; Gaal V; Cebotaru C; Guttman T; Todor N; Ghilezan N
    J BUON; 2007; 12(1):33-9. PubMed ID: 17436399
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study.
    Wozniak AJ; Crowley JJ; Balcerzak SP; Weiss GR; Spiridonidis CH; Baker LH; Albain KS; Kelly K; Taylor SA; Gandara DR; Livingston RB
    J Clin Oncol; 1998 Jul; 16(7):2459-65. PubMed ID: 9667264
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Docetaxel (Taxotere) as first-line therapy of advanced non-small cell lung cancer (NSCLC)].
    Manegold C
    Onkologie; 2003 Dec; 26 Suppl 7():26-32. PubMed ID: 14716139
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Vinorelbine in the treatment of non-small-cell lung cancer and breast cancer].
    Kubota K
    Gan To Kagaku Ryoho; 2000 Jul; 27(8):1301-6. PubMed ID: 10945030
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of advanced non-small-cell lung cancer in special populations.
    Lilenbaum RC
    Oncology (Williston Park); 2004 Sep; 18(10):1321-5; discussion 1326, 1329-33. PubMed ID: 15526837
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New options in the treatment of non-small cell lung cancer.
    Fossella F; Rigas JR; Belani CP
    Anticancer Drugs; 1999 Nov; 10 Suppl 1():S25-8. PubMed ID: 10630365
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gefitinib in the treatment of advanced non-small-cell lung cancer.
    Reck M
    Expert Rev Anticancer Ther; 2009 Apr; 9(4):401-12. PubMed ID: 19374595
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vinorelbine and carboplatin in inoperable non-small cell lung cancer: a monoinstitutional phase II study.
    Cremonesi M; Mandalà M; Cazzaniga M; Rezzani C; Gambera M; Barni S
    Oncology; 2003; 64(2):97-101. PubMed ID: 12566905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Second-line treatments of advanced non-small-cell lung cancer: new evidence for clinical practice.
    Tassinari D; Drudi F; Lazzari-Agli L; Tombesi P; Sartori S
    Ann Oncol; 2010 Feb; 21(2):428-429. PubMed ID: 19920059
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.